| Literature DB >> 34063391 |
Roland N Dickerson1, Christin N Crawford2, Melissa K Tsiu3, Cara E Bujanowski4, Edward T Van Matre1, Joseph M Swanson1, Dina M Filiberto5, Gayle Minard5.
Abstract
The intent of this study was to ascertain the prevalence of augmented renal clearance (ARC) in patients with traumatic injuries who require nutrition therapy and identify factors associated with ARC. Adult patients admitted to the trauma intensive care unit from January 2015 to September 2016 who received enteral or parenteral nutrition therapy and had a 24 h urine collection within 4 to 14 days after injury were retrospectively evaluated. Patients with a serum creatinine concentration > 1.5 mg/dL, required dialysis, or had an incomplete urine collection were excluded. ARC was defined as a measured creatinine clearance > 149 mL/min/1.73 m2. Two hundred and three patients were evaluated. One hundred and two (50%) exhibited ARC. A greater proportion of patients with ARC were male (86% vs. 67%; p = 0.004), had traumatic brain injury (33% vs. 9%; p = 0.001), a higher injury severity score (30 ± 11 vs. 26 ± 12; p = 0.015), were younger (36 ± 15 vs. 54 ± 17 years; p = 0.001), had a lower serum creatinine concentration (0.7 ± 2 vs. 0.9 ± 0.2 mg/dL; p = 0.001) and were more catabolic (nitrogen balance of -10.8 ± 13.0 vs. -6.2 ± 9.2 g/d; p = 0.004). The multivariate analysis revealed African American race and protein intake were also associated with ARC. Half of critically ill patients with traumatic injuries experience ARC. Patients with multiple risk factors for ARC should be closely evaluated for dosing of renally-eliminated electrolytes, nutrients, and medications.Entities:
Keywords: augmented renal clearance; creatinine; creatinine clearance; enteral nutrition; injury; kidney; nutrition; parenteral nutrition; protein; trauma
Year: 2021 PMID: 34063391 PMCID: PMC8156106 DOI: 10.3390/nu13051681
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Patient characteristics.
| Variable | with ARC | without ARC |
|
|---|---|---|---|
| N | 102 | 101 | - |
| Male/Female, n/n | 87/15 | 68/33 | 0.004 |
| Race, AA/White/Other | 36/57/9 | 34/60/7 | 0.209 |
| Admitting diagnosis | |||
| MVC | 75 | 64 | |
| GSW/KSW | 14 | 14 | |
| Assault/Fall | 8 | 15 | |
| Other | 5 | 5 | 0.462 |
| Age, years | 36 ± 15 | 54 ± 17 | 0.001 |
| Weight, kg | 91 ± 22 | 97 ± 27 | 0.014 |
| Height, cm | 177 ± 9 | 174 ± 11 | 0.009 |
| Body mass index, kg/m2 | 29 ± 16 | 32 ± 8 | 0.003 |
| Body surface area, m2 | 2.10 ± 0.27 | 2.15 ± 0.31 | 0.083 |
| Injury severity score | 30 ± 11 | 26 ± 12 | 0.015 |
| SOFA score | 5.6 ± 1.8 | 5.9 ± 2.4 | 0.445 |
| Ventilator dependent, | 97 (95%) | 95 (94%) | 0.987 |
| Severe traumatic brain injury, | 34 (33%) | 9 (9%) | 0.001 |
| History of diabetes mellitus, | 8 (8%) | 21 (21%) | 0.015 |
| Corticosteroids, | 13 (13%) | 13 (13%) | 0.855 |
| Vasopressors, | 12 (12%) | 21 (21%) | 0.120 |
| Neuromuscular | 6 (6%) | 11 (11%) | 0.301 |
| Beta adrenergic | 53 (52%) | 47 (47%) | 0.941 |
| Propofol, | 40 (39%) | 20 (20%) | 0.004 |
| Serum albumin, g/dL | 2.6 ± 0.5 | 2.4 ± 0.4 | 0.001 |
| Serum prealbumin, mg/dL | 7.0 ± 3.6 | 6.7 ± 4.1 | 0.460 |
| Serum C-reactive | 21.3 ± 8.1 | 19.8 ± 9.4 | 0.259 |
| Serum glucose *, mg/dL | 126 ± 31 | 135 ± 35 | 0.026 |
| White blood cell count *, cells/mm3 | 12.5 ± 4.9 | 12.8 ± 5.6 | 0.999 |
| Serum 25-hydroxy | 19.9 ± 7.4 | 19.3 ± 6.5 | 0.593 |
| Arterial pH * | 7.42 ± 0.05 | 7.41 ± 0.06 | 0.105 |
| Heart rate *, bpm | 122 ± 29 | 115 ± 21 | 0.027 |
| Minute ventilation *, L/minl | 13.1 ± 5.0 | 13.3 ± 5.0 | 0.937 |
| Maximum | 101.7 ± 1.3 | 101.3 ± 1.5 | 0.181 |
* on day of 24 h urine collection. AA, African American; ARC, augmented renal clearance as defined by a measured creatinine clearance > 149 mL/min/1.73 m2; bpm, beats per minute; GSW, gunshot wound, KSW, knife stab wound; L, liters; min, minute; MVC, motor vehicle collision; n, number; SOFA, sequential organ failure assessment. Variable missing data: injury severity score (n = 6), serum albumin (n = 21), serum prealbumin (n = 13), serum C-reactive protein (n = 14), serum 25-hydroxy vitamin D (n = 24), arterial pH (n = 16), and minute ventilation (n = 36).
Nutrition therapy.
| Variable | with ARC | without ARC |
|
|---|---|---|---|
|
| 102 | 101 | - |
| PN/EN/both | 4/87/11 | 5/76/20 | 0.177 |
| Nutrition therapy | 16.5 ± 9.5 | 20.1 ± 13.2 | 0.027 |
| Protein intake, g/d * | 110 ± 62 | 98 ± 60 | 0.165 |
| Protein intake g/kg/d * | 1.4 ± 0.8 | 1.4 ± 0.8 | 0.122 |
| Caloric intake, Kcals/d * | 1237 ± 765 | 1088 ± 754 | 0.232 |
| Caloric intake, Kcals/kg/d * | 16 ± 10 | 15 ± 10 | 0.634 |
| NBAL, g/d * | −10.8 ± 13.0 | −6.2 ± 9.2 | 0.004 |
| Hospital day of | 7 ± 3 | 8 ± 4 | 0.086 |
* on day of 24 h urine collection. ARC, augmented renal clearance as defined by a measured creatinine clearance > 149 mL/min/1.73 m2; d, days; EN, enteral nutrition; n, number; mCrCl, measured creatinine clearance; NBAL, nitrogen balance; PN, parenteral nutrition.
Clinical outcomes.
| Variable | with ARC | without ARC |
|
|---|---|---|---|
|
| 102 | 101 | - |
| Survived, | 96 (94%) | 89 (87%) | 0.209 |
| Sepsis, | 56 (55%) | 47 (46%) | 0.293 |
| Pneumonia, | 54 (53%) | 37 (36%) | 0.028 |
| Antibiotic days, d | 9 ± 7 | 10 ± 9 | 0.330 |
| Ventilator days, d | 18 ± 18 | 20 ± 19 | 0.977 |
| ICU length of stay, d | 22 ± 16 | 24 ± 19 | 0.505 |
| Hospital length | 35 ± 23 | 42 ± 38 | 0.217 |
ARC, augmented renal clearance as defined by a measured creatinine clearance > 149 mL/min/1.73 m2; d, days; ICU, intensive care unit; n, number.
Figure 1Measured creatinine clearance in patients with and without severe traumatic brain injury (TBI). * p = 0.004.
Renal function and measured creatinine clearance.
| Variable | with ARC | without ARC |
|
|---|---|---|---|
|
| 102 | 101 | - |
| Hospital day of | 7 ± 3 | 8 ± 4 | 0.086 |
| Serum creatinine, mg/dL | 0.7 ± 0.2 | 0.9 ± 0.2 | 0.001 |
| Serum urea nitrogen, mg/dL | 16 ± 2 | 23 ± 12 | 0.001 |
| Urine output, mL/d | 3045 ± 1194 | 2305 ± 1195 | 0.001 |
| Urine output, mL/kg/h | 1.67 ± 0.69 | 1.36 ± 0.73 | 0.002 |
| mCrCl, mL/min | 255 ± 76 | 135 ± 37 | 0.001 |
| mCrCl mL/min/1.73 m2 | 210 ± 38 | 109 ± 27 | 0.001 |
| Predicted CrCl | 193 ± 55 * | 125 ± 44 ** | 0.001 |
ARC, augmented renal clearance as defined by a measured creatinine clearance > 149 mL/min/1.73 m2; equation; CrCl, creatinine clearance; mCrCl, measured creatinine clearance. * p = 0.029 compared to mCrCl per 1.73 m2; ** p = 0.001 compared to mCrCl per 1.73 m2.
Figure 2Relationship between measured (mCrCL) and predicted (Cockcroft–Gault equation) creatinine clearance (pCrCL) for patients with and without augmented renal clearance. Regression equations for each group, respectively, were: mCrCL ml/min/1.73 m2 = 0.25 × pCrCL (mL/min/1.73 m2) + 163 (r = 0.23, p = 0.018) and mCrCL mL/min/1.73 m2 = 0.32 × pCrCL (mL/min/1.73 m2) + 69 (r = 0.52, p = 0.001). The regressions for those with and without ARC, adjusted for predicted creatinine clearance, were significantly different from each other by ANCOVA (p = 0.001).
Univariate correlation analysis between measured creatinine clearance and associated variables.
| Variable |
|
|
|---|---|---|
| Age, years | −0.429 | 0.001 |
| Sex, male | 0.248 | 0.001 |
| Weight, kg | −0.146 | 0.037 |
| Height, cm | 0.186 | 0.008 |
| Body mass index, kg/m2 | −0.247 | 0.001 |
| Severe traumatic brain injury | −0.199 | 0.004 |
| Diabetes mellitus | −0.142 | 0.043 |
| Pneumonia | 0.185 | 0.008 |
| Injury severity score | 0.142 | 0.047 |
| APACHE II score | −0.186 | 0.008 |
| Serum creatinine, mg/dL | −0.499 | 0.001 |
| Serum urea nitrogen, mg/dL | −0.381 | 0.001 |
| Urine output, mL/d | 0.342 | 0.001 |
| Urine output, mL/kg/h | 0.247 | 0.001 |
APACHE, acute physiology and chronic health evaluation; r, Pearson’s correlation coefficient. Variable missing data: injury severity score (n = 6).
Multivariate analysis of variables associated with augmented renal clearance. Data given as the mean (95% confidence interval).
| Variable | Odds Ratio |
|
|---|---|---|
| Male sex | 8.59 (2.69, 27.41) | 0.001 |
| Age, years | 0.95 (0.93, 0.98) | 0.001 |
| African American race | 2.73 (1.06, 7.01) | 0.037 |
| Severe traumatic brain injury | 4.14 (1.33, 12.90) | 0.014 |
| Protein intake, g/kg/d | 2.06 (1.09, 3.91) | 0.027 |
| Nitrogen balance, g/d | 0.91 (0.86, 0.95) | 0.001 |
| Serum creatinine, mg/dL | 0.00 (0.00, 0.00) | 0.001 |
| WBC, cells/mm3 | 0.928 (0.85, 1.01) | 0.096 |
WBC, white blood cell count.
Figure 3Receiver operating characteristic (ROC) curve of the logistic multiple regression analysis equation for determination of presence of ARC. Area under the ROC curve was 0.914 (95% confidence interval, 0.874, 0.955). p = 0.001.
Performance of the multivariate regression model for predicting presence of ARC.
| Model Score | Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value |
|---|---|---|---|---|
| −0.77 (mean) | 92% | 68% | 75% | 90% |
| −1.15 (95% CI) | 86% | 87% | 87% | 86% |
| −0.06 (95% CI) | 67% | 97% | 96% | 75% |
CI, confidence interval.